Lilly and Novo now look beyond US for obesity drug growth

· thehindubusinessline.com

Lilly and Novo expand global obesity drug access, introducing new treatments while addressing cost and cultural barriers.

Obesity patients at Juan Manuel Esparza Luna’s clinic in Chihuahua, Mexico, have options to slim down, with access to Novo Nordisk A/S and Eli Lilly & Co.’s...


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI